BTIG analyst Justin Zelin raised the firm’s price target on Immunocore to $91 from $85 and keeps a Buy rating on the shares. The company’s Q2 results saw an impressive beat in KIMMTRAK revenues of $57.8M, driven primarily by an increase from 50% to 60% share of 1L US. market, the analyst tells investors in a research note. KIMMTRAK has shown greater efficacy in earlier lines, and the firm sees continued growth in the 1L U.S. market, with a catalyst of 3-year OS update in 1L mUM expected in the second half of this year, BTIG adds.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore price target raised to $75 from $72 at Oppenheimer
- Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
- Immunocore reports Q2 EPS (37c), consensus (41c)
- Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
- Immunocore initiated with a Hold at Canaccord on ‘modest’ near-term growth